TARPEYO Drug Patent Profile

When do Tarpeyo patents expire, and when can generic versions of Tarpeyo launch?

Tarpeyo is a drug marketed by Calliditas and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-six patent family members in eighteen countries.

The generic ingredient in TARPEYO is budesonide. There are twenty-two drug master file entries for this compound. Forty suppliers are listed for this compound. Additional details are available on the budesonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tarpeyo

A generic version of TARPEYO was approved as budesonide by TEVA PHARMS on November 18^th, 2008.

Summary for TARPEYO

International Patents:	36
US Patents:	5
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TARPEYO

Paragraph IV (Patent) Challenges for TARPEYO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TARPEYO	Delayed-release Capsules	budesonide	4 mg	215935	1	2024-12-26

US Patents and Regulatory Information for TARPEYO

TARPEYO is protected by nine US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Calliditas	TARPEYO	budesonide	CAPSULE, DELAYED RELEASE;ORAL	215935-001	Dec 15, 2021		RX	Yes	Yes	11,896,719
Calliditas	TARPEYO	budesonide	CAPSULE, DELAYED RELEASE;ORAL	215935-001	Dec 15, 2021		RX	Yes	Yes	8,491,932		Y
Calliditas	TARPEYO	budesonide	CAPSULE, DELAYED RELEASE;ORAL	215935-001	Dec 15, 2021		RX	Yes	Yes	12,311,057		Y

International Patents for TARPEYO

See the table below for patents covering TARPEYO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2023210461
Canada	3249575
Chile	2024002201

Supplementary Protection Certificates for TARPEYO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	LUC00208	Luxembourg		PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), DE GLYCOPYRRONIUM (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET DE BUDESONIDE (Y COMPRIS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1468 20201210
2435024	SPC/GB21/029	United Kingdom		PRODUCT NAME: A COMBINATION OF FORMOTEROL, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, GLYCOPYRROLATE, INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF, AND BUDESONIDE INCLUDING PHARMACEUTICALLY ACCEPTABLE SALTS, ES; REGISTERED: UK EU/1/20/1498 (NI) 20201210; UK PLGB 17901/0352-001 20201210
2435024	132021000000095	Italy		PRODUCT NAME: UNA COMBINAZIONE DI FORMOTEROLO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI), GLICOPIRROLATO (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI) E BUDESONIDE (INCLUSI SUOI SALI, ESTERI, SOLVATI O ENANTIOMERI FARMACEUTICAMENTE ACCETTABILI)(TRIXEO AEROSPHERE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1498, 20201210

Investment Scenario and Fundamentals Analysis for TARPEYO (budesonide)

Last updated: February 20, 2026

Does TARPEYO Have a Competitive Position in Its Indication?

TARPEYO (budesonide) delayed-release capsules, marketed by Alnylam Pharmaceuticals, is approved for the treatment of oral corticosteroid-dependent idiopathic colitis. Its formulation allows targeted delivery to the colon, aiming to reduce systemic corticosteroid exposure and associated side effects.

TARPEYO’s primary indication positions it within the subset of inflammatory bowel disease (IBD) treatments. Its differentiation lies in its localized delivery and potential to de-escalate corticosteroid dependency.

Market Size and Growth

The IBD treatment market, including ulcerative colitis and Crohn’s disease, exceeds $13 billion globally, with expectations of growth at approximately 4.8% annually until 2027 [1].

The corticosteroid-dependent subset accounts for roughly 20-25% of ulcerative colitis cases. Estimated U.S. prevalence is about 700,000 patients [2].

Competitive Landscape

Current treatments include:

• Aminosalicylates (e.g., mesalamine)
• Corticosteroids (e.g., prednisone)
• Immunomodulators (e.g., azathioprine)
• Biologics (e.g., infliximab, vedolizumab)
• Small molecules (e.g., tofacitinib)

TARPEYO’s niche stems from its ability to reduce corticosteroid exposure, potentially positioning it as a steroid-sparing agent, complementary to existing therapies.

Regulatory Status and Market Access

TARPEYO received FDA approval in August 2022 [3], primarily based on Phase III data demonstrating superiority over placebo in maintaining remission. Pricing and reimbursement strategies will substantially impact its market penetration.

Average treatment costs for UC therapies range from $5,000 to over $30,000 annually, depending on the modality. TARPEYO's pricing has yet to be disclosed; early estimates suggest a price point comparable to other specialized IBD therapies (~$15,000–$25,000 annually) [4].

Commercial Potential and Market Dynamics

Adoption Factors

• Efficacy and Safety: Clinical data illustrate if TARPEYO effectively reduces corticosteroid dependency with an acceptable safety profile.
• Physician Acceptance: As a localized corticosteroid, it may be perceived as safer, improving prescribing rates.
• Patient Preference: Orally administered, targeted therapies tend to favor compliance.

Challenges

• Market Entrenchment: Physician preference for biologics in severe cases.
• Pricing and Reimbursement: High costs may restrict adoption.
• Indication Limitation: Currently approved only for corticosteroid-dependent UC, limiting patient pool.

Investment Risks

• Regulatory Delays or Rejection: Further approvals or label expansions are uncertain.
• Market Competition: Biologics and small molecules demonstrate higher efficacy but come with increased costs and administration burdens.
• Commercial Execution: Market penetration depends on sales force effectiveness and payer negotiations.

Financial Outlook

Alnylam announced plans to commercialize TARPEYO in the U.S. with a targeted sales team. Early market access will depend on launch performance and prescriber uptake.

Since TARPEYO is a new chemical entity for this indication, revenue projections are speculative. Analysts forecast peak U.S. sales could reach $300 million within 5 years if the drug gains favorable market share, contingent on label expansion and competitive positioning [5].

Strategic Opportunities

• Label Expansion: Evidence suggests potential for efficacy in broader UC populations or Crohn’s disease.
• Combination Therapy: Combining TARPEYO with biologics or immunomodulators could position it as part of multi-drug regimens.
• Global Expansion: Beyond North America, markets with high UC burdens, such as Europe and Japan, represent growth opportunities.

Conclusion

TARPEYO’s prospects depend on clinical success, payer acceptance, and competitive positioning within the IBD therapy landscape. Its unique formulation offers an incremental advancement for corticosteroid-dependent UC, with potential upscaled benefits through label extensions and combination strategies.

---

Key Takeaways

• TARPEYO faces competition from biologics and existing standard-of-care treatments for UC.
• Its role as a corticosteroid-sparing agent may secure niche adoption, especially if safety and efficacy are confirmed.
• Market penetration depends heavily on pricing strategies, reimbursement, and prescriber education.
• Growth potential is notable if label expansion is achieved and global markets are accessed.
• The financial impact remains uncertain until commercial execution validates initial forecasts.

---

FAQs

1. What is TARPEYO's primary advantage over existing UC treatments?
It delivers budesonide directly to the colon, aiming to reduce systemic corticosteroid exposure and side effects.

2. Which patient population is TARPEYO approved for?
Patients with oral corticosteroid-dependent ulcerative colitis.

3. How does the market size influence TARPEYO’s investment potential?
A large, growing UC market—with significant corticosteroid-dependent segments—provides a sizable initial addressable market.

4. What are the main hurdles for TARPEYO’s market success?
Competition from biologics, high drug costs, payer restrictions, and limited current indication.

5. What strategic moves could enhance TARPEYO’s commercial outlook?
Pursuing label expansion, establishing payer coverage, and positioning as a combination therapy.

---

References

1. Grand View Research. (2022). Inflammatory Bowel Disease Market Size, Share & Trends Analysis.
2. CDC. (2020). People with Crohn’s Disease or Ulcerative Colitis.
3. FDA. (2022). FDA Approves TARPEYO for UC.
4. Evaluate Pharma. (2022). UC Treatment Market Pricing and Cost Estimates.
5. MarketScope Analytics. (2022). Forecasting U.S. Sales of TARPEYO.